Scancell to join Nasdaq through Neuphoria merger and $89 million funding package

Scancell Holdings PLC ( AIM:SCLP, OTC:SCNLF, FRA:SCP ) View Price & Profile Scancell to join Nasdaq through Neuphoria merger and $89 million funding package Published: 08:35 23 Jul 2026 BST Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) , the Oxford-based cancer immunotherapy developer listed on London's junior AIM market, has agreed an all-share merger with US biotech Neuphoria Therapeutics that will give it a Nasdaq listing and access to American investors.

The combined group will keep the Scancell name and apply to trade on Nasdaq under the ticker SCLT, while retaining its existing AIM quotation. Alongside the deal, Scancell expects to raise up to $89 million through a mix of equity and debt to fund a global registrational phase III trial of its lead treatment in advanced melanoma. The company has secured commitments from new and existing shareholders for a private placement of $39.1 million, roughly £29.2 million. It is launching a UK placing today to raise about $12 million and a retail offer of up to $3 million.

Scancell has also signed a non-binding term sheet with funds managed by BlackRock for debt financing of up to $25 million. Completion of the merger is expected to bring at least a further $10 million into the enlarged group from Neuphoria's own cash balances. Existing Scancell shareholders will own 85.5% of the combined company on a pro forma basis, with Neuphoria holders taking 14.5%. The lead asset, iSCIB1+, is an off-the-shelf immunotherapy designed to prompt the patient's own immune system to attack tumour cells. It has fast-track designation from the US Food and Drug Administration, a status intended to speed the review of treatments addressing serious condi...